TR202022087A2 - Inhalation Powder for SARS Cov-2 Infections - Google Patents
Inhalation Powder for SARS Cov-2 Infections Download PDFInfo
- Publication number
- TR202022087A2 TR202022087A2 TR2020/22087A TR202022087A TR202022087A2 TR 202022087 A2 TR202022087 A2 TR 202022087A2 TR 2020/22087 A TR2020/22087 A TR 2020/22087A TR 202022087 A TR202022087 A TR 202022087A TR 202022087 A2 TR202022087 A2 TR 202022087A2
- Authority
- TR
- Turkey
- Prior art keywords
- infections
- carvacrol
- essential oil
- inhalation
- capsule
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 12
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 11
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 13
- 239000000341 volatile oil Substances 0.000 claims abstract description 13
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims abstract description 12
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000007746 carvacrol Nutrition 0.000 claims abstract description 12
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000004072 lung Anatomy 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000020610 powder formula Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 150000002936 p-menthane-3,8-diol derivatives Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Abstract
Bu buluşta SARS Cov-2 enfeksiyonlarında karvakrol ve eucalyptus uçucu yağı kombine edilerek doğrudan toz halde akciğere verilmek için formüle edilmiştir. Kısaca SARS Cov-2 enfeksiyonlarının önlenmesinde ve tedavisinde kullanılabilecek kombine inhalasyon tozu ve hazırlanmasını açıklamaktadır.In this invention, in SARS Cov-2 infections, carvacrol and eucalyptus essential oil are combined and formulated to be administered directly to the lungs in powder form. Briefly describes the combined inhalation powder and its preparation that can be used in the prevention and treatment of SARS Cov-2 infections.
Description
TARIFNAME SARS Cov-2 Enfeksiyonlari Için Inhalasyon Tozu Teknik Alan Bu bulus inhalasyon yoluyla hastalara verilmek üzere gelistirilmis eucalyptus uçucu yagi ve karvakrol içeren tercihen bomeolunde kullanildigi kum toz formülü hakkindadir. Önceki Teknik Su anda COVlD-l9'a neden olan koronavirüs olan SARS-COV-Z'yi tedavi etmek için antiviral olarak remdesivir ve favipiravir kullanilmaktadir. Ancak bunlarin hastaya uygulanmasi invaziv ve zordur. Bu ilaçlari içeren inhalasyon yolu ile verilebilecek kuru toz formülü mevcut degildir. Remdesivir SARS-CoV-Z'yi tedavi etmek için genellikle intravenöz uygulama ile infüzyon halinde verilir. DESCRIPTION Inhalation Powder for SARS Cov-2 Infections Technical Area This invention was developed to be administered to patients by inhalation eucalyptus. Sand powder formula containing essential oil and carvacrol, preferably used in bomeol. is about. Prior Art Treating SARS-COV-Z, the coronavirus that currently causes COVID-19 Remdesivir and favipiravir are used as antivirals. However, these It is invasive and difficult to administer to the patient. By inhalation containing these drugs There is no dry powder formula that can be given. Remdesivir SARS-CoV-Z It is usually given as an infusion by intravenous administration to treat
Remdesivir, agir hastalik nedeniyle hastaneye yatirilan yetiskin ve pediatrik hastalarda acil durumlarda kullanilmaktadir. Ilk önceleri Ebola virüsü hastaligini tedavi etmek için gelistirilen remdesivir, insan hava yolu epitel hücrelerinde COVlD-19'u tedavi etmek için umut verici sonuçlar göstermistir. Bununla birlikte, sinirli etkili uygulama yöntemleri, yasami tehdit eden semptomlar sergileyen hastalara yaygin tedavi uygulama çabalarini engellemistir. Remdesivir is used in adult and pediatric hospitalized patients with severe illness. used in emergencies. First, the Ebola virus disease Remdesivir, developed to treat human airway epithelial cells It has shown promising results for treating COVID-19. With this However, limited effective methods of administration, life-threatening symptoms This has hindered efforts to apply widespread treatment to patients with
SARS-COV-2 virüsünün ilk yerlestigi bölge üst solunum yoludur. Bu nedenle günlük hayatin içinde virüsün yerlesmesini engelleyecek virüsün ilk yerlesim bölgesinde çogalmasini önleyecek formülasyonlara ihtiyaç bulunmaktadir. The first location of the SARS-COV-2 virus is the upper respiratory tract. Because the first settlement of the virus that will prevent the virus from settling in daily life. There is a need for formulations to prevent proliferation in the region.
Bogaz pastilleri bu nedenle sikça tercih edilen ürünler olmakla beraber seker içerikleri nedeni ile bazen kullanimlari tercih edilmemektedir. For this reason, throat lozenges are frequently preferred products. Sometimes their use is not preferred due to their content.
Antimikrobiyal etkinligi bilinen çok sayida bitki ve bitkisel madde bulunmaktadir. There are many plants and herbal substances with known antimicrobial activity.
Bunlarin çok farkli kombinasyonlarinin yapilmasi mümkündür. Bu antimikrobiyal ajanlarda daha çok bakteriyel enfeksiyonlar için kombine edilmis olup viral enfeksiyonlar için gelistirilmis ürünlerin sayisi sinirlidir. ekstresini benzalkonyum klorür ile birlikte içeren antiviral kombinasyonlar hakkindadir. içeren ürünler hakkindadir. It is possible to make many different combinations of these. This antimicrobial agents are mostly combined for bacterial infections and viral The number of products developed for infections is limited. antiviral combinations containing the extract together with benzalkonium chloride is about. about products containing
USZOO4/007l757 numarali patent basvurusu solunum yolu enfeksiyonlarinda intranasal yama kullanilmasi hakkindadir. Bu basvuru kombinasyonda kullanilan bilesiklerden çok uygulama metodu hakkindadir. Patent application numbered USZOO4/007l757 on respiratory tract infections It is about using an intranasal patch. This reference is used in combination it is more about the method of application than about the compounds.
EP1748769 numarali patent basvurusu daha önce antiseptik antifungal antibakteriyel etkisi gösterilmis p-mentan-3,8-diol bilesiklerinin antiviral olarak kullanilmasi hakkindadir. Patent application number EP1748769 was previously applied to antiseptic antifungal Antiviral use of p-menthane-3,8-diol compounds with antibacterial effects it is about to be used.
Bu buluslarin hiçbirisi Viral enfeksiyonlarda kullanilacak hizli ve etkili kombinasyonlar ve bunlarin formülasyonlari hakkinda degildir. Yine bu buluslarin hiçbiri SARS CoV-2 enfeksiyonlarindan korunma metodu hakkinda degildir. None of these inventions are quick and effective for use in viral infections. It is not about combinations and their formulations. again this none of the inventions about the method of protection from SARS CoV-2 infections is not.
Uygulamasi kolay etkili ve güvenilir antiviral kompozisyonlarinin gelistirilmesine ihtiyaç vardir. To develop effective and safe antiviral compositions that are easy to apply. there is a need.
Bu bulus SARS CoV-Z viral enfeksiyonlardan korunmada ve viral enfeksiyon tedavisine yardimci, uygulamasi kolay, güvenilir kombinasyonlar ve bu kombinasyonlarin hazirlanma metodu hakkindadir. This invention provides protection from SARS CoV-Z viral infections and viral infection. easy to apply, reliable combinations that help in the treatment of It is about the method of preparation of combinations.
Bulusun çözümünü amaçladigi teknik problemler Bu bulus eucalyptus uçucu yagi ve karvakrol içeren inhalasyon yoluyla hastalara verilmek üzere gelistirilmis kuru toz formülüdür. Bu bulus COVlD-l9 hastalarini tedavi etmek için inhalasyon yoluyla dogrudan akcigerlere verilebilecek toz formülasyonunu ve bunun nasil hazirlanacagini anlatir. Bugüne kadar Eucalyptus uçucu yagi ve Karvakrolü bir arada içeren ve inhalasyon yoluyla kullanilabilecek bir toz formülü gelistirilmemistir. Technical problems that the invention aims to solve This invention is administered to patients via inhalation containing eucalyptus essential oil and carvacrol. It is a dry powder formula developed for administration. This invention treats COVID-19 patients powder that can be inhaled directly into the lungs to treat explains its formulation and how to prepare it. Eucalyptus to date It contains essential oil and Carvacrol together and can be used by inhalation. a powder formula has not been developed.
COVID-l9 hastaligi tedavisi zor bir hastaliktir. COVID-l9 hastaliginda yan etkisi çok fazla olan ilaçlarin yerine eucalyptus uçucu yagi ve karvakrolun hedef dokulara dogrudan ulasmasini saglayan ürünler etkin bir tedavi saglayacaktir. COVID-19 is a difficult disease to treat. Side effect in COVID-19 disease target of eucalyptus essential oil and carvacrol instead of drugs that are too much Products that allow it to reach the tissues directly will provide an effective treatment.
Tedavisi zor olan bu hastalikta uygulama kolayligi olan ürün gelistirilerek hem hastane yükü azaltilacak hem de özellikle yasli hastalarda ölüm risklerini artiran yan etki insidansinin azaltilmasi amaçlanmistir. In this disease, which is difficult to treat, a product that is easy to apply has been developed and both the hospital burden will be reduced and the risk of death will increase, especially in elderly patients. It is aimed to reduce the incidence of side effects.
Yine bu bulusta antiviral etkinin güçlendirilmesi için ayni formülasyon içerisine diger antiviral ajanlar katilabilir. Diger antiviral ajanlar arasinda borneol, epigallokatesin galat sayilabilir. Diger antiviral ajanlarin sayisi burada anlatilanlarla sinirli degildir. Again, in this invention, it is included in the same formulation to strengthen the antiviral effect. Other antiviral agents may be added. Other antiviral agents include borneol, epigallocatecin can be considered gallate. Number of other antiviral agents here is not limited by what is told.
SARS CoV-Z enfeksiyonun tedavisinde eucalyptus uçucu yagi ve karvakrolun bir arada veya gerektiginde bir baska antiviral ajanla kullanilmasi, dozlari ve hazirlama teknigi belli degildir, bu bulus bunlari açiklamaktadir. A combination of eucalyptus essential oil and carvacrol in the treatment of SARS CoV-Z infection. its use with another antiviral agent in between or when necessary, its doses and preparation technique is unclear, which this invention explains.
Bulusun Açiklamasi Bu bulusta antiviral ajanin inhalasyona uygun toz formülü hazirlanmistir. Bunun için antiviral ajan etanolde çözülür ve laktoza püskürtülerek kaplanir. Antiviral ajanin etanoldeki çözeltisi 10 mg/ml olmalidir. Laktoz olarak %50-75 oranda 1-3 mikrometre inhalasyona uygun laktoz tozuna etanolde çözülmüs lÜmg/ml antiviral bilesik püskürtülür. Akiskan yatak Cihazinda 50°C”yi geçmeyen isida kaplama yapilir. Sert jelatin kapsüle dolum yapilarak inhalasyon yolu ile hastaya verilir. Inhalasyon cihazi olarak herhangi bir inhalasyon cihazi kullanilabilir. Description of the Invention In this invention, powder formula of antiviral agent suitable for inhalation is prepared. This The antiviral agent is dissolved in ethanol and spray coated with lactose. antiviral The solution of the agent in ethanol should be 10 mg/ml. 50-75% as lactose 1-3 Micrometer to lactose powder suitable for inhalation dissolved in ethanol IUmg/ml antiviral compound is sprayed. Temperature not exceeding 50°C in the fluidized bed device coating is done. It is filled into a hard gelatin capsule and given to the patient by inhalation. is given. Any inhaler can be used as an inhaler.
Antiviral ajan olarak bu bulusta eucalyptus uçucu yagi ve karvakrol tercih edilmistir. Bu iki antiviral ajan istenirse diger antiviral ajanlarla, antienflamatuvar ajanlarla kombine edilebilir. Kombine edilecek diger ajanlar arasinda borneol ve epigallokatesin gallat tercih edilir. Eucalyptus essential oil and carvacrol were preferred in this invention as antiviral agents. has been made. These two antiviral agents can be combined with other antiviral agents if desired. Can be combined with agents. Other agents to be combined include borneol and epigallocatecin gallate is preferred.
Bu bulustaki kombinasyon asagidaki sekilde hazirlanabilir. Eucalyptus uçucu yagi ve karvakrol 0.5-1 mg/ml olacak sekilde etanolde çözülür ve inhalasyona uygun laktoz tozuna püskürtülerek fludized bed (Akiskan yatak) Cihazinda kaplanir ve 50°C”yi geçmeyen sicakliklar kullanilarak kaplanir. Kaplama sonunda miktar tayini yapildiginda 1 doz tozda yaklasik 0.5 -1 mg eucalyptus uçucu yagi ve 0.5 -1 mg karvakrol olmalidir. Bu sekilde hazirlanan toz dogrudan nefesle akcigerlere alinmak üzere sert jelatin veya benzeri kapsüllere doldurulup inhalasyonla hastalara verilir. Inhalasyonla verilecek cihaz herhangi bir toz inhalasyon cihazi olabilir. The combination in this invention can be prepared as follows. Eucalyptus essential oil and carvacrol are dissolved in ethanol as 0.5-1 mg/ml and suitable for inhalation. It is sprayed on lactose powder and coated in a fludized bed device and It is coated using temperatures not exceeding 50°C. Quantity at the end of coating When the determination is made, approximately 0.5 -1 mg of eucalyptus essential oil and 0.5 -1 mg of eucalyptus essential oil in 1 dose of powder mg of carvacrol. The powder prepared in this way is directly breathed into the lungs. It is filled into hard gelatin or similar capsules to be taken and administered by inhalation. given to patients. The device for inhalation is any powder inhaler it could be.
Bu bulusta antiviral kombinasyonuna ek antiviral veya antienflamatuvar etkisi ile bilinen diger ajanlar katilabilir. Diger ajanlar arasinda bomeol, epigallokatesin gallat sayilabilir. Bulusun diger antiviral ve antienflamatuvar ajanlarla kombinasyonu burada anlatilanlarla sinirli degildir. In this invention, it has an antiviral or anti-inflammatory effect in addition to the antiviral combination. Other known agents may be involved. Other agents include bomeol, epigallocatecin gallates. of the invention with other antiviral and anti-inflammatory agents. combination is not limited to what is described here.
Bulusun sanayiye uygulanma biçimi Bu bulusta verilen formül akiskan yatak cihazinda inhalasyona uygun laktoza yüklenir ve kurutulur. Daha sonra kapsül doldurma cihazinda istenen miktarlar sert jelatin kapsüllere doldunilur ve blister ambalaj içine konulur. Sanayide rutinde kullanilan cihaz ve ekipman ile çok kolaylikla üretilebilecek bir formüldür. How the invention is applied to industry The formula given in this invention is lactose suitable for inhalation in a fluidized bed device. loaded and dried. Then the desired quantities in the capsule filling device filled into hard gelatin capsules and placed in blister packs. in industry It is a product that can be produced very easily with the devices and equipment used in the routine. is the formula.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2020/22087A TR202022087A2 (en) | 2020-12-28 | 2020-12-28 | Inhalation Powder for SARS Cov-2 Infections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2020/22087A TR202022087A2 (en) | 2020-12-28 | 2020-12-28 | Inhalation Powder for SARS Cov-2 Infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR202022087A2 true TR202022087A2 (en) | 2021-01-21 |
Family
ID=75576137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2020/22087A TR202022087A2 (en) | 2020-12-28 | 2020-12-28 | Inhalation Powder for SARS Cov-2 Infections |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR202022087A2 (en) |
-
2020
- 2020-12-28 TR TR2020/22087A patent/TR202022087A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210244705A1 (en) | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| AU2010335594B2 (en) | Synergistic antiviral composition and use thereof | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP6234899B2 (en) | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis | |
| JP2022019937A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| CN107998110A (en) | Resveratrol is used to prepare treatment or alleviates the purposes of chronic inflammatory airway disease medicine | |
| JP2005508963A (en) | Pharmaceutical combination containing salmeterol and fluticasone propionate to treat asthma | |
| RU2010120806A (en) | MONTELUKAST ACID INHALATION COMPOSITIONS AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | |
| TR202022087A2 (en) | Inhalation Powder for SARS Cov-2 Infections | |
| KR860003018A (en) | Medical treatment of non-viral diseases of human body using 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide | |
| WO2021195017A1 (en) | Iodine compounds for treating respiratory pathogens | |
| Misra | A short review on important drugs under clinical trial against Covid-19 | |
| KR880003973A (en) | Pharmacologically active compounds and uses | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| Shahani et al. | Status of chloroquine and hydroxychloroquine in COVID-19 infection | |
| TR2022000350A2 (en) | Inhalation Product Containing Eucalyptus | |
| TR202015068A2 (en) | Inhalation Powder Containing Combined Antiviral Agent for the Treatment of COVID-19 | |
| US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
| Sultana et al. | Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning | |
| JP2021161105A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| WO2022224464A1 (en) | Phytochemical composition | |
| CN108283629A (en) | Sucking roflumilast suspension and preparation method thereof | |
| Hussain et al. | Nigella Sativa: An Immunity Booster as Pandemic Treatment Solution Against SARS-CoV-2 | |
| WO2021198739A1 (en) | Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions |